Johnson & Johnson $JNJ Shares Sold by Belpointe Asset Management LLC

Belpointe Asset Management LLC lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 52.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 15,207 shares of the company’s stock after selling 16,982 shares during the quarter. Belpointe Asset Management LLC’s holdings in Johnson & Johnson were worth $2,323,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of JNJ. Highline Wealth Partners LLC lifted its stake in shares of Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after purchasing an additional 86 shares in the last quarter. Stone House Investment Management LLC acquired a new position in shares of Johnson & Johnson in the first quarter worth about $47,000. 1248 Management LLC acquired a new position in shares of Johnson & Johnson in the first quarter worth about $48,000. von Borstel & Associates Inc. acquired a new position in shares of Johnson & Johnson in the first quarter worth about $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in shares of Johnson & Johnson in the first quarter worth about $52,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.4%

NYSE:JNJ opened at $188.95 on Wednesday. The firm has a market capitalization of $455.06 billion, a PE ratio of 20.21, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. The stock has a 50 day moving average of $177.04 and a 200-day moving average of $163.18. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $189.92. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business’s revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the company earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. Johnson & Johnson’s payout ratio is currently 55.61%.

Wall Street Analyst Weigh In

Several research firms recently commented on JNJ. UBS Group set a $198.00 price target on Johnson & Johnson in a research note on Friday. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Johnson & Johnson in a research note on Saturday, September 27th. HSBC boosted their price target on Johnson & Johnson from $188.00 to $210.00 in a research note on Tuesday, September 30th. Finally, Royal Bank Of Canada boosted their price objective on Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $189.88.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.